Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Shareholder Meeting (November 2014)
33 slides from Immutep's shareholder meeting presentation, Nov 14, 2014
Slide 1: CEO Presentation - Annual General Meeting
Exhibit 99.1 CEO Presentation Annual General Meeting Marc Voigt, CEO 14 November 2014 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD; Deutsche Börse:YP1B.DE). These slides have been prepared as a presentation aid only and the information they contain may require furth
Slide 3: Cancer Immunotherapy - Way of the future
Cancer Immunotherapy - Way of the future “Immunotherapy – the beginning of the end for cancer” Immunotherapies -$35bn potential/ annum. Will likely become the treatment backbone in up to 60% of cancers in the next 10 years Andrew S Baum Citi Equities Research 22 May 2013
Slide 4: Prima in Prime Position!
Prima in Prime Position! Immunotherapy rapidly growing & evolving industry Multiple approaches with multiple products – diversified portfolio Leading edge research & IP generating new candidates Strong commercial partnerships with potential future revenues Strong research team and advisory boards Po
Slide 5: Prima's Potential in Multiple Approaches
Prima‘s Potential in Multiple Approaches Cellular therapy, Antibody therapy … CVac Turn on the immune system Release the brakes Immune checkpoint agents, Antibody therapy … IMP701 Push the gas Cytokine therapy, Antibody therapy … IMP321
Slide 6: Pipeline
Pipeline Partner Preclinical Phase I Phase IIa Phase IIb Phase III Indication Neopharm Group (for Israel ) Neopharm Group (for Israel ) Eddingpharm (for China ) CVac IMP321 CVac Ovarian Cancer Pancreatic Cancer Metastatic Breast Cancer + Chemotherapy Eddingpharm (for China ) IMP321 Metastatic Renal
Slide 7: New Prima BioMed
New Prima BioMed Portfolio of advanced products as well as R&D Strong partnerships with big pharma companies (GSK, Novartis, Eddingpharm, Neopharm) Partly no development costs = lower risk Ongoing revenue potential: milestones are near- mid- and long-term oriented Global grant options in Australia,
Slide 8: Expanded Operational Management Team
Expanded Operational Management Team Christian Toloczyki, PhD, Director Quality Assurance 25+ years’ experience in the pharmaceutical, biotechnological and medical device industries and strong background in quality assurance processes by holding different positions with responsibility for developmen
Slide 9: Upcoming Catalysts in CY2015
Upcoming Catalysts in CY2015 Start of new clinical trial with IMP321 Continued development of phase I study with IMP731 Potential material milestone payments during 2015 (GSK) Start of phase I study with IMP701 (Novartis) CVac: patient recruitment of CAN-004B and CAN-301, Final OS readout of CAN-003
Slide 10: Financial Data FY2014
FINANCIAL DATA FY2014 10 ® PRIMA BIOMED
Slide 11: Key Financial Data of FY 2014
Key Financial Data of FY 2014 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 30 June 2014 30 June 2013 30 June 2012 TOTAL OTHER INCOME $ 3.140.066 $ 4.005.394 $ 4.202.567 Expenses Research & development and intellectual property $ (11.930.857) $ (14.005.259) $ (15.118.816) Corporate administrative e
Slide 12: Immutep Transaction
IMMUTEP TRANSACTION 2 ® PRIMA BIOMED
Slide 13: Consideration
Consideration Total consideration up to approx. US$28M: – US$18M in cash (US$10.8M upfront payment; 40% based on milestones/retention) – US$3M in ordinary PRR shares – 200M options and warrants (approx. US$7M in value) partly dependent on milestones Consideration in context: Average upfront payment
Slide 14: CVac Overview
CVAC OVERVIEW 0 ® PRIMA BIOMED
Slide 15: FY2014 CVac in review
FY2014 CVac in review CAN-003 Very Positive Interim Overall Survival Data:> 36Mo CVac vs 25.53Mo OSC Clear Target Patient Population identified of 2nd remission EOC patients Observation continues CAN-004B 2nd remission EOC patients, enrolment ongoing (21 sites active) -> more sites will be activated
Slide 16: Ovarian Cancer - Second Remission
Ovarian Cancer- Second Remission Overall Survival 1.00 0.75 0.50 0.25 0.00 OSC: median OS 25.53 mos CVAC:median OS not reached yet Hazard ratio 0.17 (95% Cl:0.02, 1.44) P=0.07 by log-rank test (2sided) Median follow-up 36 months 0 6 12 18 24 Months 30 36 42 48 osc CVAC 1/10 0/8 0/8 O/7 0/7 O/7 0/6 0
Slide 17: Clinical & Manufacturing Priorities
Clinical & Manufacturing Priorities In general: active management of clinical development program to ensure best potential clinical benefit and optimal capital allocation Review CAN-004A trial in light of CAN-003 results, Immutep acquisition and clinical development priorities of IMP321, CAN-004B an
Slide 18: Outlook
OUTLOOK 18 ® PRIMA BIOMED
Slide 19: Outlook for CY 2015
Outlook for CY 2015 Continued development of CVac: Recruitment of CAN-004 (B): Ovarian cancer in 2nd remission Recruitment of CAN-301: Pancreatic cancer Continued refinement & optimisation of manufacturing Final OS data of CAN-003 Start of new trial with IMP321 Continued development of phase I study
Slide 20: Prima Value Drivers
Prima Value Drivers Diversified portfolio in one of the most interesting fields of immuno-oncology Good Intellectual Property position & regulatory advantages (e.g. Fast Track in US) Excellent partnerships with the pharmaceutical industry and other research partners Potential revenues from milestone
Slide 21: Thank You!
THANK YOU! a1 ® PRIMA BIOMED
Slide 22: Professor Frédéric Triebel Presentation
Professor Frédéric Triebel Presentation to the Annual General Meeting of Shareholders 14 November 2014 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034
Slide 23: Cancer Immunotherapy
Cancer Immunotherapy (Immuno-Oncology : “IO”) A quick lesson!
Slide 24: Why do we get cancer?
Why do we get cancer? Our immune system is trained to tell the difference between self and non-self Cancers have clever escape mechanisms that allow them to hide If the immune system can’t see a cancer cell, it can’t kill it If the cancer cell turns off immune cells, they can’t be killed Immunothera
Slide 25: What are T cells and APC?
What are T cells and APC? APC are antigen presenting cells – they show antigens to T cells Dendritic cells are an important type of APC In cancer, APC show antigen to T cells to activate them T cells have a number of functions In cancer the role of T cells is to – Stimulate production of anti-cancer
Slide 26: Dendritic Cells & IMP321
Dendritic Cells & IMP321 Dendritic cells (DC) and monocytes/macrophages form a network in tissues DC cover 25% of human skin surface area thanks to their long dendrites This dendritic network is a 1st line of defenseDendrites (immune surveillance) against pathogens or tumor cells Activating this net
Slide 27: What is LAG-3?
What is LAG-3? Lymphocyte Activation Gene 3 = LAG-3 Can both inhibit and activate immune responses LAG-3 on the surface of T cells can inhibit their function by signalling or putting on the brakes LAG-3 binding to molecules on APC’s called MHC can activate them to present antigen to T cells LAG-3 re
Slide 28: Immutep's LAG-3 products
Immutep’s LAG-3 products IMP321, IMP731 and IMP701
Slide 29: Immutep's Dual Technology Platform
Immutep’s Dual Technology Platform LAG-3 immune control mechanism Activator Inhibitor IMP321 Soluble form of LAG-3 used - in chemo-immunotherapy - as a T cell adjuvant in therapeutic vaccines - Eddingpharm licence (China) IMP731 / IMP701 LAG-3 on T cells as a target for therapeutic antibodies - IMP7
Slide 30: Immutep's First-In Class Activator
Immutep’s First-In Class Activator IMP321
Slide 31: IMP321 – How does it work?
IMP321 – How does it work? DC/monocytes activated: stimulates expansion of activated T cells Immature DC Activated DC/monocytes CD8 T cell expansion MHC II LAG-3Ig (IMP321) Primary target cells IMP321 (LAG-3Ig) Secondary target cells highly efficacious in multiple animal models of cancer and infecti
Slide 32: Future plans
Future plans Completion of IMP321 manufacturing in 2015 Planning of new IMP321 clinical trial will commence after AGM Potential new trials in metastatic breast cancer and/or in combination with other options R&D on preclinical candidates to continue GSK and Novartis could enter phase I
Slide 33: Thank You!
THANK YOU! 2 ® PRIMA BIOMED